OWP Pharmaceuticals Logo
Subvenite® (lamotrigine) Oral Suspension Logo

Disclaimer

Effective Date: September 21, 2026

The information available through subvenite.com is provided by OWP Pharmaceuticals, Inc. for general educational and informational purposes concerning SUBVENITE® (lamotrigine) oral suspension.

Not Medical Advice

Website content is not medical advice and is not intended to diagnose, treat, cure, or prevent any disease or medical condition. It does not replace consultation with a qualified healthcare professional.

Do not start, stop, or change a medication or treatment based solely on Website content. Patients should discuss questions with their healthcare professionals. Healthcare professionals remain solely responsible for exercising independent clinical judgment.

Emergencies and Safety Reporting

This Website is not monitored as an emergency or immediate-response service. For a medical emergency, call 911 or seek immediate medical care.

Do not submit adverse-event reports, medical records, diagnoses, prescriptions, or patient-identifying information through the general contact email or email-update form. Follow the medical-information and safety-reporting instructions displayed on the Website.

Full Prescribing Information

Always review the current FDA-approved Full Prescribing Information, including the Boxed Warning and Medication Guide where applicable. If Website content differs from the current FDA-approved labeling, the FDA-approved labeling controls.

Dosing Tools

Any dosing calculator or similar tool is supplemental and does not replace the Full Prescribing Information, professional judgment, independent verification, or assessment of an individual patient. OWP does not warrant the accuracy or suitability of calculator inputs, outputs, or results for any particular patient.

No Guarantee of Results

Individual treatment responses vary. Nothing on the Website guarantees a clinical outcome, treatment result, medication suitability, coverage decision, product availability, reimbursement, or savings-program eligibility.

Accuracy and Timeliness

OWP seeks to provide useful information but does not warrant that all Website content is complete, error-free, current, or continuously available. Medical, regulatory, reimbursement, and product information may change. OWP may correct or update content without notice.

Third-Party Content

Links and references to third-party websites, services, pharmacies, publications, organizations, or resources are provided for convenience. OWP does not control and is not responsible for their content, availability, privacy, security, accuracy, or practices. A link does not necessarily constitute endorsement.

Limitation

To the fullest extent permitted by law, OWP disclaims liability arising from reliance on Website content or the use, inability to use, interruption, error, or omission of the Website. Nothing in this Disclaimer excludes any liability or legal right that cannot lawfully be excluded.

United States Use

The Website is intended for United States residents. Product indications, labeling, approvals, and availability may differ in other countries. Access outside the United States does not constitute marketing or an offer in another jurisdiction.

Contact

OWP Pharmaceuticals, Inc.
701 Warrenville Road, Suite 200
Lisle, IL 60532
Telephone: 1-800-273-6729
Email: info@owppharma.com

Subvenite® (lamotrigine) Oral Suspension logo icon

© 2025 OWP Pharmaceuticals, Inc. All rights reserved.
Naperville, IL 60563. Developed in USA.

You are now leaving Subvenite.com

Links to all outside sites are provided as a resource to our visitors. OWP Pharmaceuticals accepts no responsibility for the content of the sites that are not owned and operated by OWP Pharmaceuticals.

Continue
Cancel

You are now leaving Subvenite.com

Links to all outside sites are provided as a resource to our visitors. OWP Pharmaceuticals accepts no responsibility for the content of the sites that are not owned and operated by OWP Pharmaceuticals.

Continue
Cancel
Important Safety Information & Resources

WARNING: SERIOUS SKIN RASHES

See full prescribing information for complete boxed warning.

Cases of life-threatening serious rashes, including Stevens-Johnson syndrome and toxic epidermal necrolysis, and/or rash-related death have been caused by lamotrigine, the active ingredient in SUBVENITE. The rate of serious rash is greater in pediatric patients than in adults. Additional factors that may increase the risk of rash include:

  • coadministration with valproate.
  • exceeding recommended initial dose of SUBVENITE.
  • exceeding recommended dose escalation for SUBVENITE.
  • presence of the HLA-B*1502 allele. (5.1)

Benign rashes are also caused by lamotrigine, the active ingredient in SUBVENITE; however, it is not possible to predict which rashes will prove to be serious or life threatening. SUBVENITE should be discontinued at the first sign of rash, unless the rash is clearly not drug related. (5.1)
 

SUBVENITE is indicated for:
Epilepsy—adjunctive therapy in patients aged 2 years and older:

  • partial-onset seizures
  • primary generalized tonic-clonic (PGTC) seizures
  • generalized seizures of Lennox-Gastaut syndrome. (1.1)
 

Epilepsy—monotherapy in patients aged 16 years and older: Conversion to monotherapy in patients with partial-onset seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug. (1.1)

Bipolar disorder: Maintenance treatment of bipolar I disorder to delay the time to occurrence of mood episodes in patients treated for acute mood episodes with standard therapy. (1.2)

Limitations of Use: Treatment of acute manic or mixed episodes is not recommended. Effectiveness of SUBVENITE in the acute treatment of mood episodes has not been established.

DOSAGE AND ADMINISTRATION

  • Dosing is based on concomitant medications, indication, and patient age. (2.1, 2.2, 2.3, 2.4)
  • To avoid an increased risk of rash, the recommended initial dose and subsequent dose escalations should not be exceeded. (2.1, 16)
  • Do not restart SUBVENITE in patients who discontinued due to rash unless the potential benefits clearly outweigh the risks. (2.1, 5.1)
  • Adjustments to maintenance doses will be necessary in most patients starting or stopping estrogen-containing products, including oral contraceptives. (2.1, 5.9)
  • Discontinuation: Taper over a period of at least 2 weeks (approximately 50% dose reduction per week). (2.1, 5.10)
 

Epilepsy:
Adjunctive therapy—See Table 1 for patients older than 12 years and Tables 2 and 3 for patients aged 2 to 12 years. (2.2)
Conversion to monotherapy—See Table 4. (2.3)
Bipolar disorder: See Tables 5 and 6. (2.4)

DOSAGE FORMS AND STRENGTHS

  • Oral Suspension: 10 mg/mL (3)
 

CONTRAINDICATIONS

Hypersensitivity to the drug or its ingredients. (Boxed Warning, 4)

WARNINGS & PRECAUTIONS

  • Life-threatening serious rash and/or rash-related death: Discontinue at the first sign of rash, unless the rash is clearly not drug related. (Boxed Warning, 5.1).
  • Hemophagocytic lymphohistiocytosis: Consider this diagnosis and evaluate patients immediately if they develop signs or symptoms of systemic inflammation. Discontinue lamotrigine if an alternative etiology is not established. (5.2)
  • Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)/Multiorgan Hypersensitivity: Discontinue if no alternate etiology. (5.3)
  • Cardiac rhythm and conduction abnormalities: Can cause cardiac rhythm and conduction abnormalities, particularly in patients with underlying cardiac disorders or arrhythmias. (5.4)
  • Blood dyscrasias (e.g., neutropenia, thrombocytopenia, pancytopenia): May occur, either with or without an associated hypersensitivity syndrome. Monitor for signs of anemia, unexpected infection, or bleeding. (5.5)
  • Suicidal behavior and ideation: Monitor for suicidal thoughts or behaviors. (5.6)
  • Aseptic meningitis: Monitor for signs of meningitis. (5.7)
  • Medication errors due to product name confusion: Strongly advise patients to visually inspect the product to verify the received drug is correct. (5.8, 16, 17)
 

ADVERSE REACTIONS

Epilepsy: Most common adverse reactions (incidence ≥10%) in adults were dizziness, headache, diplopia, ataxia, nausea, blurred vision, somnolence, rhinitis, pharyngitis, and rash. Additional adverse reactions (incidence ≥10%) reported in children included vomiting, infection, fever, accidental injury, diarrhea, abdominal pain, and tremor. (6.1)

Bipolar Disorder: Most common adverse reactions (incidence >5%) in adults were nausea, insomnia, somnolence, back pain, fatigue, rash, rhinitis, abdominal pain, and xerostomia. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact OWP Pharmaceuticals Inc. at 1-800-273-6729 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

  • Valproate increases lamotrigine concentrations more than 2-fold. (7, 12.3)
  • Carbamazepine, phenytoin, phenobarbital, primidone, and rifampin decrease lamotrigine concentrations by approximately 40%. (7, 12.3)
  • Estrogen-containing oral contraceptives decrease lamotrigine concentrations by approximately 50%. (7, 12.3)
  • Protease inhibitors lopinavir/ritonavir and atazanavir/lopinavir decrease lamotrigine exposure by approximately 50% and 32%, respectively. (7, 12.3)
  • Coadministration with organic cationic transporter 2 substrates with narrow therapeutic index is not recommended (7, 12.3)
 

USE IN SPECIFIC POPULATIONS

  • Pregnancy: Based on animal data may cause fetal harm. (8.1)
  • Hepatic impairment: Dosage adjustments required in patients with moderate and severe liver impairment. (2.1, 8.6)
  • Renal impairment: Reduced maintenance doses may be effective for patients with significant renal impairment. (2.1, 8.7)
 

See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.

Please refer to the full Prescribing Information for SUBVENITE at www.subvenite.com.

08/2026
Resources